Skip to main content

6-K

Indivior Pharmaceuticals, Inc. (INDV)

6-K 2025-02-12 For: 2025-02-12
View Original
Added on April 10, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

________________________

Washington, D.C. 20549

_____________________

FORM 6-K

_____________________

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of February 2025

Commission File Number: 001-37835

________________________________________

Indivior PLC

________________________________________

10710 Midlothian Turnpike, Suite 125

North Chesterfield, Virginia 23235

(Address of principal executive office)

_______________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit No. Description of Exhibit
99.1 Announcement sent<br>to the London Stock Exchange on February 12, 2025, titled<br>“Delayed FDA Approval of SUBLOCADE Label<br>Changes”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Indivior PLC
Date: February 12, 2025 /s/<br>Kathryn Hudson
Name:<br>Kathryn Hudson
Title:<br>Company Secretary

a7798w-58126621

Exhibit 99.1

RNS STATEMENT RE: DELAYED FDA APPROVAL of SUBLOCADE LABEL CHANGES

RELEASE DATE:<br> FEBRUARY 12, 2025<br><br><br><br><br><br>RELEASE TIME:<br> 7:00 AM GMT

Indivior provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE® (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:

Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.

Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.

-ends-